Xintela

Xintela Quick Ratio

The Quick Ratio (Acid Test) of Xintela (XINT.ST) as of Nov 5, 2026 is 0.72. In the previous year, Quick Ratio (Acid Test) was 0.80 — a change of -10.43% (lower).

Quick Ratio

0.72

YoY

-10.43%

Last updated:

Quick Ratio (Acid Test) of Xintela is 2025 0.72 . Quick Ratio (Acid Test) of Xintela was 2024 0.80 . It decreases by -10.43% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Xintela Stock analysis

What does Xintela do? Xintela AB, based in Lund, Skåne, develops pharmaceutical products in the Health Care sector, specifically focusing on regenerative medicine for cartilage damage and osteoarthritis, as well as treatments for glioblastoma brain tumors. The company utilizes therapeutic antibodies and XINMARK, a marker technology using specific proteins to identify stem cells for cartilage development. Listed on 22 March 2016, Xintela operates within biotechnology, targeting innovative therapies in oncology and orthopedics. Xintela is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Xintela stock

Quick Ratio (Acid Test) of Xintela is 0.72 in 2025.

Quick Ratio (Acid Test) of Xintela changed from 0.80 to 0.72, representing a -10.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Xintela since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Xintela with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Xintela

All Key Metrics — Xintela